natgillin/translations-raw huggingface dataset:
n = antal tilfælde (2) ATP-kohorte: inkluderede kvinder, som havde fået 3 vaccinedoser, og som var DNA-negative ved måned 0 og ved måned 6 overfor den relevante HPV-type.
n= number of cases (1) ATP: includes women who received 3 doses of vaccine, were DNA negative at month 0 and at month 6 to the relevant HPV type.
n = antal tilfælde (3) ATP-kohorte: inkluderede kvinder, som havde fået 3 vaccinedoser, og som var DNA-negative ved måned 0 og ved måned 6 overfor den relevante HPV-type.
n= number of cases (1) ATP: includes women who received 3 doses of vaccine, were DNA negative at month 0 and at month 6 to the relevant HPV type.
n = randomiserede patienter, som fik mindst 1 dosis af studiemedicinen
n = randomised patients who received at least 1 dose of study medication
N = totalt antal behandlede patienter.
N = total number of patients treated.
n =12
N=12
n =162 n =162 n = 164 n = 164
n = n = n = n = 162 162 164 164 wk wk wk wk 12 24a 12 24a
n af levende,
SAG2 strain
n afspejler randomiserede og behandlede patienter
n reflects randomised and treated patients
N Antal patienter, der kan evalueres ved livskvalitetsanalyser.
N Number of patients evaluable for quality of life analyses
N Antal randomiserede patienter.
N Number of patients randomised
N er antallet af forsøgspersoner pr. modelestimat. p-værdier for lurasidon vs. placebo blev justeret for multiple sammenligninger.
N is number of subjects per model estimate. p-values for lurasidone vs. placebo were adjusted for multiple comparisons.
N er antallet af randomiserede forsøgspersoner med mindst én dosis af dobbeltblindet medicin under kortvarig dobbeltblindt behandling. n = antal forsøgspersoner med baseline-værdi og uge 24-værdi.
N is the number of randomized subjects with at least one dose of double-blind medicine during short-term double-blind treatment. n = number of subjects with non-missing baseline and a Week 24 value.
N gennemført
N completed
N graviditeter
N pregnancies
N hændelser/patienter (%)
N events/patients (%)
N konverteret
N in conversion
N patienter Gefitinib v.
N patients Gefitinib v.
n product n product
product
N randomiseret
N randomised
N tilmeldt
N entered
n) Navn
name
N+-glucuronide; andre inkluderede N-desmethylasenapin, N-desmethylasenapin N-carbamoyl glucuronide og uomdannet asenapin i mindre mængder.
N+-glucuronide; others included N-desmethylasenapine, N-desmethylasenapine N-carbamoyl glucuronide, and unchanged asenapine in smaller amounts.
N, N-Diethyl-m-toluamid 1-Methoxy-2-propylacetat Dimethylsulfoxid
N, N-Diethyl-m-toluamide 1-Methoxy-2-propyl-acetate Dimethyl sulfoxide
N- demethylering af methylnaltrexonbromid til naltrexon er ikke signifikant og udgør 0,06 % af den administrerede dosis.
N-demethylation of methylnaltrexone bromide to produce naltrexone is not significant, accounting for 0.06 % of the administered dose.
N-(carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamin (MPEG-2000-DSPE), saccharoseoctasulfat, 2- [4- (2-hydroxyethyl)piperazin-1-yl]ethansulfonsyre (HEPES-buffer), natriumchlorid og vand til injektionsvæsker.
N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoly-sn-glycero-3-phosphoethanolam ine (MPEG-2000-DSPE); Sucrose octasulphate; 2- [4- (2-Hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES buffer); sodium chloride and water for injections.
N-2409 Elverum Norge
N-2409 Elverum Norway
N-2409 Elverum Norge
NO-2409 Elverum Norway
N-acetylglutamatsyntasemangel (NAGS).
N-acetylglutamate synthase (NAGS) deficiency.
N-acetylglutamatsyntasemangel:
For N-acetylglutamate synthase deficiency:
N-dealkylbuprenorphin er en -opioidagonist med svag instrinsic activity.
N-dealkylbuprenorphine is a -opioid agonist with weak intrinsic activity.
N-dealkylbuprenorphin er en -opioidagonist med svag intrinsic activity.
N-dealkylbuprenorphine is a -opioid agonist with weak intrinsic activity.
N-demethylerede derivat af ivabradin er identificeret som den aktive hovedmetabolit hos mennesker.
The N- desmethylated derivative of ivabradine has been identified as the main active metabolite in humans.
N-demethylering, katalyseret af CYP1A1, CYP3A4, CYP2C8 og CYP2J2 er den primære biotransformationsvej for riociguat, og fører til den primære cirkulerende aktive metabolit M-1 (farmakologisk aktivitet: 1/10 til 1/3 af riociguat), som metaboliseres videre til det farmakologisk inaktive N-glucuronid.
N-demethylation, catalysed by CYP1A1, CYP3A4, CYP2C8 and CYP2J2 is the major biotransformation pathway of riociguat leading to its major circulating active metabolite M-1 (pharmacological activity: 1/10th to 1/3rd of riociguat) which is further metabolised to the pharmacologically inactive N-glucuronide.
N-desethyl-brinzolamid er brinzolamids primære metabolit, der dannes i mennesker, og som ligeledes bindes til CA-I i brinzolamids tilstedeværelse og akkumuleres i RBC.
N-desethyl brinzolamide is a major metabolite of brinzolamide formed in humans, which also binds to CA-I in the presence of brinzolamide and accumulates in RBCs.
N-desethylbrinzolamid hæmmer ikke cytokrom P450-isozymer ved koncentrationer på mindst 100-gange over de maksimale systemiske niveauer.
N-desethylbrinzolamide do not inhibit cytochrome P450 isozymes at concentrations at least 100-fold above maximum systemic levels.
N-desmethyl-enzalutamid (aktivt) og et carboxylsyrederivat (inaktivt).
N-desmethyl enzalutamide (active) and a carboxylic acid derivative (inactive).
N-desmethyl-enzalutamid blev ikke metaboliseret af CYP-isoenzymer in vitro.
N-desmethyl enzalutamide was not metabolized by CYPs in vitro.
N-desmethylmetabolitten i gennemsnit med mindre end 7 % (spændvidde 4 - 9 %) af det samlede lægemiddelstofrelaterede materiale, som blev fundet i urin og fæces.
Overall, the N-desmethyl metabolite contributed a mean of less than 7% (range 4-9 %) of the total medicinal product related material accounted for in the urine and faeces.
N-desmetyl-vandetanib produceres primært via CYP3A4, og vandetanib-N-oxid af de flavinholdige monooxygenase-enzymer FM01 og FMO3.
N-desmethyl-vandetanib is primarily produced by CYP3A4, and vandetanib-N-oxide by flavin-containing monooxygenase enzymes (FM01 and FMO3).
N-desmetylsildenafil
N-desmethyl-sildenafil
N-monodesmethyl (M2).
N-monodesmethyl metabolite (M2).
N-monodesmethyl diltiazem: AUC: ↓ 37% (↓ 17 til ↓ 52)
N-monodesmethyl diltiazem: AUC: 0 37% (0 17 to 0 52)
N-octyl-2-pyrrolidon N-methylpyrrolidon
N-octyl-2-pyrrolidone N-methylpyrrolidone
N-vandetani b
n-vandetanib
N. gonorrhoeae Utilstrækkelig evidens
N. gonorrhoeae IE (insufficient evidence)
n.a.
0.0007
n.a.
36
N.V. Bristol-Myers Squibb Belgium S.A. Tél/Tel: + 32 2 352 76 11
N.V. Bristol-Myers Squibb Belgium S.A.
N.V. Organon Kloosterstraat 6 5349 AB Oss Holland
N.V. Organon Kloosterstraat 6 5349 AB Oss The Netherlands
N.V. Organon Kloosterstraat 6 NL- 5349 AB Oss Holland
N.V. Organon Kloosterstraat 6 NL- 5349 AB Oss The Netherlands
N.V. Organon Kloosterstraat 6 NL-5349 AB Oss Holland
N.V. Organon Kloosterstraat 6 NL-5349 AB Oss The Netherlands
N.V. Organon Veersemeer 4 5347 JN Oss Holland
N.V. Organon Veersemeer 4, 5347 JN Oss The Netherlands
N.V. Organon Veersemeer 4 5347 JN Oss Holland‌
N.V. Organon Veersemeer 4 5347 JN Oss The Netherlands
N.V. Organon, Kloosterstraat 6, 5349 AB Oss, Holland
N.V. Organon, Kloosterstraat 6, 5349 AB Oss, The Netherlands
N.V. Organon, Kloosterstraat 6, 5349 AB Oss, Holland
N.V. Organon, Kloosterstraat 6, 5349 AB Oss, The Netherlands.
N.V. Organon, Kloosterstraat 6, NL-5349 AB Oss, Holland
N.V. Organon, Kloosterstraat 6, NL-5349 AB Oss, The Netherlands
N.V.Organon
N.V. Organon
N/A
0.045
N/A
1/2
N/A = Ikke relevant
N/A = not applicable
n/a = not applicable - ikke relevant a BMD Z-score ikke justeret for højde og vægt b Primært sikkerhedsendepunkt indtil uge 72
NA = Not Applicable a BMD Z-scores not adjusted for height and weight b Primary safety endpoint through week 72
N/A: Ikke relevant
N/A: Not Applicable
N/A†
177
n/N
24/25
n/N % 95 %-KI n/N % 95 %-KI
n/N % 95% CI n/N % 95% CI
N139T
G138E
N298S
M296I
N320I
I319T
N: Antal inkluderede patienter
N: number of patients enrolled
n: respons-evaluerbare patienter
n: response-evaluable patients
n:respons-evaluerbare patienter
n: response-evaluable patients
N= 1.800
N = 1,800
N= 1.802
N = 1,802
N= 134
Panretin N= 134
n= 181
n = 181
N= 229
N=229
N= 466
N = 466
N= 480
N = 480
N= 527
N = 527
N= antal inkluderede personer i hver gruppe n= antal personer som rapporterte mindst et tilfælde i hver gruppe 6-månders PI= 6-måneders persisterende infektion
N= number of subject in each group n= number of subjects reporting at least one event in each group 6M PI = 6-month persistent infection
N=1.149 100 % (99-100)
N=1149 100% (99-100)
N=1.152 100 % (99-100)
N=1152 100% (99-100)
N=1.152 84 % (82-86)
N=1152 84% (82-86)
n=10 for AUC12t
2,711 ± 2,268
N=100 N=99
Seroneutralization rate
n=101
n= 101
n=106
0.006
n=106 11,7 (10,2-17,4)
n=106 11.7 (10.2-17.4)
N=109 100 % (97-100)
N=109 100% (97-100)
N=109 95 % (90-98)
N=109 95% (90-98)
N=111 100 % (97-100)
N=111 100% (97-100)
N=111 77 % (68-84)
N=111 77% (68-84)
N=123 til 220†
N=123 to 220
N=126*
N = 126
N=127 (ITT-
N=127 (ITT
N=128
Study V87P13
n=128 15,7
n=128 15.7
N=130 (ITT-
N=130 (ITT
N=140 100 % (97-100)
N=140 100% (97-100)
N=140 86 % (80-92)
N=140 86% (80-92)
N=146
N = 146
N=157 76,5 (68,5;
N=157 76.5 (68.5,
N=17 N=19
(14.2; 61.7) (82.4; 100.0)
N=179 100 % (98-100)
N=179 100% (98-100)
n=180
3 weeks n=180
n=197
n=294
N=197
SRH
N=197
Study V87P11
n=197
‐0.5
N=2.609
N=2,609
N=2.635
N=2,635
N=2.676
N=2,676
N=2.679
N=2,679
N=2.689
N=2,689
N=2.701
N=2,701
N=207
SRH
N=207*
N =207
N=207*
N =421
N=208 100 % (98-100)
N=208 100% (98-100)
N=209
N = 209
N=210
Study V87P11
N=211 81 % (75-86)
N=211 81% (75-86)
N=212 100 % (98-100)
N=212 100% (98-100)
N=212 96 % (93-98)
N=212 96% (93-98)
N=229
N = 229
N=238
N= 238
N=240 (ITT-
N=130 (ITT
N=242 (ITT-
N=127 (ITT
N=242 (ITT-population)
N=242 (ITT population)
N=244
N = 244
N=244 84,6 (79,0;
N=244 84.6 (79.0,
n=249
n = 249
n=252
n = 252
n=259
n = 259
N=266 59,0 (52,9;
N=266 59.0
n=268 (95% konfidens- interval)
n=268 (95% confidence interval)
N=268 90 % (86-93)
N=268 90% (86-93)
N=269 100 % (99-100)
N=269 100% (99-100)
N=27
N=31
n=2748 5,6 %
n=2,748 5.6
n=278
3 weeks n=278
N=288 91,3 (86,8;
N=288 91.3 (86.8,
N=29
N=33
n=294
0.9
n=294
‐9.1
N=330
N= 330
n=331
population)
N=333
N= 333
n=336
N=240 (ITT
N=34
N=47
N=346
difference)
N=346
N=343
N=369 100 % (98-100)
N=369 100% (98-100)
N=37 19 % (8-35)
N=37 19% (8-35)
N=4 150
Enoxaparin/VKAb)
N=411
N = 411
N=421*
N =207
N=421*
N =421
N=426
N = 426
N=427 100 % (98-100)
N=427 100% (98-100)
N=427 100 % (99-100)
N=427 100% (99-100)
N=43 1.447 N=36 305 N=25 32 N=31 44
N=43 1447 N=36 305 N=25 32 N=31 44
N=472
N=444
N=50
N=51
N=51
80.0% 88.0
N=51
N=50
N=60)
N=60
N=64 14,4 (6,0;
N=64 14.4 (6.0,26.4)
N=66
Study V87P13
n=74
146 (46)
n=74*
n=74
n=8 100 % p<0,005*
n=8 100% p<0.005
n=863
N = 863
N=90
N/A
N=934 til 1270‡
N=934 to 1270
N=94
N=96
n=96
n= 96
N=Antal bivirkninger/antal randomiserede patienter;
N=Number of events/number of randomised patients;
N=Antal personer randomiseret til den respektive vaccinationsgruppe, som fik mindst en injektion. n=Antal personer der bidrog til analysen.
N= Number of individuals randomized to the respective vaccination group who received at least one injection. n= Number of individuals contributing to the analysis.
N=Antal personer, der var randomiseret til den respektive vaccinationsgruppe, der fik mindst én injektion. n=Antal personer, der bidrog til analysen.
N=Number of individuals randomized to the respective vaccination group who received at least one injection. n=Number of individuals contributing to the analysis.
N=Antallet af personer med mindst 1 opfølgningsbesøg efter måned 7.
N=Number of individuals with at least 1 follow-up visit after Month 7.
n=Randomiserede patienter (primær efficacy-intention-to-treat analyse) med tilgængelige data.
n=Randomized patients (primary efficacy-intention-to-treat analysis) with data available.
NA
15.8
NA (NA til NA)
NA (NA to NA)
NA = ikke tilgængelig/ikke relevant
NA = not available/not applicable
Na de 300 mg/75 mg-dosering was de antiplaatjesrespons gedaald bij de slechte metabolisers met gemiddelde IPA (5 μM ADP) van 24% (24 uur) en 37% (Dag 5) vergeleken met IPA van 39% (24 uur) en 58% (Dag 5) bij de snelle metabolisers en 37% (24 uur) en 60% (Dag 5) bij de matige metabolisers.
After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers.
Na een eenmalige orale dosis van 75 mg is de halfwaardetijd van clopidogrel ongeveer 6 uur.
After a single oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours.
Na een orale dosis van C14-gemerkte clopidogrel bij de mens werd ongeveer 50 % uitgescheiden in de urine en 46 % in de faeces in een interval van 120 uur na inname.
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
Na eenmalige en herhaalde orale doses van 75 mg per dag wordt clopidogrel snel geabsorbeerd.
After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.
Na herhaalde doses van 75 mg clopidogrel per dag bij personen met een ernstige nierfunctiestoornis (creatinineklaring van 5 tot 15 ml/min) was de remming van de ADP-afhankelijke bloedplaatjesaggregatie lager (25 %) dan die waargenomen bij gezonde proefpersonen, alhoewel de verlenging van de bloedingstijd vergelijkbaar was met die waargenomen bij gezonde proefpersonen die 75 mg clopidogrel per dag kregen.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Na herhaalde doses van 75 mg clopidogrel per dag gedurende 10 dagen bij patiënten met ernstige leverinsufficiëntie was de remming van ADP-geïnduceerde bloedplaatjesaggregatie vergelijkbaar met die van gezonde proefpersonen.
After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.
NA: Ikke tilgængelig $ Antallet af fuldt vaccinerede (2 doser) samt uvaccinerede tilfælde og kontrolgrupper er anført.
NA: Not available $ The number of fully vaccinated (2 doses) and unvaccinated cases and controls is given.
NA: Ikke tilgængelig (ikke nået).
NA: Not Available (Not Reached)
NA= Ikke relevant
NA= not applicable
NA= Ikke relevant.
NA = not applicable.
NA=ikke relevant
NA = Not applicable
Naam en adres van de fabrikant verantwoordelijk voor vrijgifte
Name and address of the manufacturer responsible for batch release
NAAM EN ADRES VAN DE HOUDER VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
NAAM VAN DE HOUDER VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN
NAME OF THE MARKETING AUTHORISATION HOLDER
NAAM VAN HET GENEESMIDDEL
NAME OF THE MEDICINAL PRODUCT
Naarden Holland
The Netherlands
NAD(P)H-dehydrogenase, quinon 1; [NQO1]).
NAD(P)H dehydrogenase, quinone 1; [NQO1]).
NadA, 94 % og 90 % for PorA P1.4 samt 89 % og 72 % for NHBA.
NadA; 94% and 90% for PorA P1.4; 89% and 72% for NHBA.
Nadir ANC (celler/l)
Nadir ANC (cells/l)
Nadir for trombocytter < 50.000 /mm3 med blødninga uanset ANC-nadir
Nadir platelets <50,000/mm3 with bleedinga, aregardless of nadir ANC
Nadir for trombocytter < 50.000 /mm3 med blødninga uanset ANC-nadir
Nadir platelets <50,000/mm3 with bleedinga, regardless of nadir ANC
Nadir for trombocytter < 50.000/mm3 med blødninga uanset ANC-nadir
Nadir platelets < 50,000 /mm3 with bleedinga, regardless of nadir ANC
Nadir for trombocytter < 50.000/mm3 med blødninga, uanset ANC-nadir
Nadir platelets < 50,000/mm3 with bleedinga, regardless of nadir ANC
Nadir for trombocytter < 50.000/mm³ med blødninga uanset ANC- nadir
Nadir platelets < 50,000/mm³ with bleedinga, regardless of nadir ANC
Nadir trombocyttal (celler/l)
Nadir Platelet Count (cells/l)
Nadir-ANC < 500/mm3 i > 1 uge
Nadir ANC <500/mm3 for > 1 week
NADPH (nicotinamidadenindinucleotidphosphat)-reduktasemangel.
Deficiency in NADPH (nicotinamide adenine dinucleotide phosphate) reductase.
nafcillin (til behandling af infektioner)
nafcillin (to treat infections)
Naglazyme 1 mg/ml koncentrat til infusionsvæske, opløsning
Naglazyme 1 mg/ml concentrate for solution for infusion
Naglazyme 1 mg/ml koncentrat til infusionsvæske, opløsning Galsulfase
Naglazyme 1 mg/ml concentrate for solution for infusion Galsulfase
Naglazyme bør ikke bruges under graviditet, medmindre det er tvingende nødvendigt.
Naglazyme should not be given during pregnancy unless clearly necessary.
Naglazyme er blevet godkendt under ”særlige omstændigheder”.
Naglazyme has been authorised under ‘exceptional circumstances’.
Naglazyme er godkendt under ”særlige omstændigheder”.
This medicine has been authorised under “exceptional circumstances”.
Naglazyme indgives under overvågning af en sygeplejerske eller læge, og han eller hun vil kontrollere, at den korrekte dosis gives og om nødvendigt give passende behandling.
Naglazyme is administered under the supervision of a nurse or doctor, he or she will check that the correct dose has been given and act accordingly if necessary.
Naglazyme må ikke blandes med andre lægemidler i samme infusion end med dem, der er anført nedenfor.
Naglazyme should not be mixed with other medicinal products in the same infusion, except for those mentioned below.
Naive (tidligere ubehandlede) patienter
Naïve patients
Nakkesmerter
Neck pain
Nakkesmerter
Oedema
nakkesmerter influenzalignende sygdom
neck pain influenza like illness
Nakkesmerter Muskuloskeletale brystsmerter
Neck pain Musculoskeletal chest pain
Nakkesmerter, brystsmerter
Neck pain, chest pain
nakkesmerter, rygsmerter
neck pain, back pain
Nakkesmerter, rygsmerter, smerter i ekstremiteter
Back pain, neck pain, pain in extremity
Nakkesmerter, stivhed i bevægeapparatet, hævelse af led, muskelkramper, skuldersmerter, muskuloskeletale smerter i brystregionen, muskuloskeletale smerter, ledstivhed, artrit, muskelsvækkelse
Neck pain, musculoskeletal stiffness, joint swelling, muscle spasms, shoulder pain, musculoskeletal chest pain, musculoskeletal pain, joint stiffness, arthritis, muscular weakness
Nakkestivhed Trismus
Nuchal rigidity Trismus
Nalmefen
Nalmefene
Naloxegol er en perifert virkende my-opioidreceptorantagonist med begrænset adgang til centralnervesystemet (CNS).
Naloxegol is a peripherally acting mu-opioid receptor antagonist with restricted access to the central nervous system (CNS).
Naloxegol er et PEGyleret derivat af my-opioidreceptorantagonisten naloxon.
Naloxegol is a PEGylated derivative of the mu-opioid receptor antagonist naloxone.
Naloxegol skal ordineres med forsigtighed til sådanne patienter under hensyntagen til deres individuelle benefit/risk-forhold, og de skal holdes under observation for potentielle CNS-virkninger, såsom symptomer på opioidabstinenser og/eller forstyrrelser i opioidmedieret analgesi.
Naloxegol should be prescribed with caution in such patients taking into account their individual benefit-risk balance with observation for potential CNS effects, such as symptoms of opioid withdrawal and/or interference with opioid-mediated analgesia.
Naloxon AUC: ↓28%
Naloxone AUC: ↓28
naloxon Cmaks. ↑ 9 %
igns of opiate toxicity
Naloxon Cmax: ↓28%
Naloxone Cmax: ↓28
Naloxon, til behandling af afhængighed og abstinenser af opioider (fx morphin).
Naloxone, used to treat opiate drug addiction and withdrawal.
Naltrexon og 6-beta-naltrexol metaboliseres ikke af cytochrom P450-enzymer og in vitro- undersøgelser indikerer, at der ikke er potentiale for hæmning eller induktion af vigtige isozymer.
Naltrexone and 6-beta-naltrexol are not metabolised by cytochrome P450 enzymes and in vitro studies indicate that there is no potential for inhibition or induction of important isozymes.
Naltrexon og bupropion er kendt for blive udskilt af nyrerne i væsentlig grad og risikoen for bivirkninger af naltrexon/bupropion kan være større hos patienter med nedsat nyrefunktion, en tilstand, der er mere normal hos ældre personer.
Naltrexone and bupropion are known to be substantially excreted by the kidney, and the risk of adverse reactions to naltrexone / bupropion may be greater in patients with impaired renal function, a condition that is more common in elderly individuals.
Naltrexon og bupropion og deres metabolitter udskilles i human mælk.
Naltrexone and bupropion and their metabolites are excreted in human milk.
naltrexon og nalmefen er opioidantagonister, der kan blokere de farmakologiske virkninger af buprenorphin.
naltrexone and nalmefene are opioid antagonists that can block the pharmacological effects of buprenorphine.
Naltrexon/bupropion anbefales ikke til patienter med let til moderat nedsat leverfunktion.
Naltrexone / bupropion is not recommended in patients with mild or moderate hepatic impairment.
Naltrexon/bupropion er ikke blevet evalueret hos patienter med nedsat leverfunktion.
Naltrexone / bupropion has not been evaluated in subjects with hepatic impairment.
Naltrexon/bupropion er ikke blevet grundigt evalueret hos patienter med nedsat nyrefunktion.
Naltrexone / bupropion has not been extensively evaluated in subjects with renal insufficiency.
Naltrexon/bupropion er kontraindiceret hos patienter med svær nedsat leverfunktion og anbefales ikke til patienter med mild til moderat nedsat leverfunktion.
Naltrexone / bupropion is contraindicated in patients with severe hepatic impairment and is not recommended in patients with mild or moderate hepatic impairment.
Naltrexon/bupropion er kontraindiceret hos patienter med svært nedsat leverfunktion og anbefales ikke til patienter med mild til moderat nedsat leverfunktion.
Naltrexone / bupropion is contraindicated in patients with severe hepatic impairment, and not recommended in patients with mild or moderate hepatic impairment (see sections 4.2, 4.8, and 5.2).
Naltrexon/bupropion er kontraindiceret hos patienter med tumor i centralnervesystemet, svært nedsat leverfunktion, nuværende eller tidligere diagnose af bulimi eller anorexia nervosa, eller afvænning fra beroligende midler (se pkt 4.3).
Naltrexone / bupropion is contraindicated in patients with central nervous system tumour, severe hepatic impairment, current or previous diagnosis of bulimia or anorexia nervosa, or withdrawal from sedatives (see section 4.3).
Naltrexon/bupropion er kontraindiceret til patienter med svær nedsat leverfunktion (se pkt.
Naltrexone / bupropion is contraindicated in patients with severe hepatic impairment (see sections 4.3,
Naltrexon/bupropion er kontraindiceret ved nyresvigt i terminalfasen eller hos patienter med svært nedsat nyrefunktion og anbefales ikke til patienter med moderat nedsat nyrefunktion.
Naltrexone / bupropion is contraindicated in endstage renal failure or patients with severe renal impairment, and is not recommended in patients with moderate renal impairment.
Naltrexon/bupropion har en ubetydelig indvirkning på evnen til at køre eller bruge maskiner.
Naltrexone / bupropion has minor influence on the ability to drive and use machines.
Naltrexon/bupropion indeholder bupropion, en dopamin- og noradrenalin-reuptake-hæmmer, der svarer til nogle aktive stoffer, der anvendes til behandling af depression.
Naltrexone / bupropion contains bupropion, a dopamine and norepinephrine re-uptake inhibitor that is similar to some active substances used for the treatment of depression.
nanog/ml
ng/ml
NANV OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Naproxen (500 mg, enkeltdosis) hæmmer af P-gp, men ikke af CYP3A4, øgede henholdvis det gennemsnitlige AUC og Cmax med en faktor 1,5 og 1,6.
Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax, respectively.